Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer

The non-alcoholic fatty liver disease market size is supposed to grow during the forecast period owing to the expected launch of novel emerging therapies, which shall fuel the growth of the non-alcoholic fatty liver disease market during the forecast period, i.e., 2023–2032.

 LAS VEGAS , Jan. 22, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Fatty Liver Disease Market Insights report includes a comprehensive understanding of current treatment practices, NAFLD emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Non-Alcoholic Fatty Liver Disease Market Report

• According to DelveInsight's analysis, the market size for NAFLD across the 7MM is expected to grow with a significant CAGR by 2032.
• DelveInsight's analysis reveals that in the US most cases of NAFLD are found to be in between 40-60 years old adults compared to the 16-39 age group in 2022. 
• Leading non-alcoholic fatty liver disease companies such as MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others are developing novel NAFLD drugs that can be available in the NAFLD market in the coming years.
• The promising non-alcoholic fatty liver disease therapies in the pipeline include MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others.

Discover which therapies are expected to grab the major NAFLD market share @ Non-Alcoholic Fatty Liver Disease Market Report

Non-Alcoholic Fatty Liver Disease Overview

Non-alcoholic fatty liver disease (NAFLD) is a comprehensive term encompassing a range of liver conditions involving the accumulation of fat, spanning from basic steatosis to more advanced stages characterized by associated hepatitis, fibrosis, cirrhosis, and, in some instances, hepatocellular carcinoma. While many individuals may harbor liver fat without evident symptoms or complications, in certain cases, the deposited fat triggers inflammation, leading to cellular damage and impaired liver functionality. The precise cause of NAFLD remains unknown, but it is often associated with factors such as overweight or obesity, type 2 diabetes or pre-diabetes, abnormal lipid levels in the blood, among others.

For most individuals, there are no discernible symptoms, but in some cases, inflammation from the fat can damage liver cells, hindering the organ's proper function. The likelihood of developing NAFLD, whether in the form of simple fatty liver or non-alcoholic steatohepatitis (NASH), increases with factors like excess weight, type 2 diabetes or pre-diabetes, and abnormal lipid levels in the blood. A definitive diagnosis of NASH can only be established through a liver biopsy, which not only confirms the condition but also provides insights into the severity of the disease. Importantly, liver biopsy is more adept at detecting fibrosis at earlier stages than elastography.

Non-Alcoholic Fatty Liver Disease Epidemiology Segmentation

The NAFLD epidemiology section provides insights into the historical and current NAFLD patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The NAFLD market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total NAFLD Prevalent Cases
• NAFLD Gender-specific Prevalent Cases
• NAFLD Age-specific Prevalent Cases 
• NAFLD Stage-specific Prevalent Cases 
• NAFLD Diagnosed and Treatable Cases 

Non-Alcoholic Fatty Liver Disease Treatment Market 

Currently, there are no approved treatments for NAFLD by regulatory agencies such as the FDA, EMA, or PMDA. However, researchers are exploring potential medications to address this condition. The primary approach for treating NAFLD involves lifestyle changes, including adjustments to diet and exercise. In addition to these modifications, alternative options for treating non-alcoholic steatohepatitis (NASH) have involved the off-label use of vitamin E and anti-diabetes medications like pioglitazone and liraglutide. The NAFLD practice guidance from the American Association for the Study of Liver Diseases (AASLD) suggests considering the off-label use of vitamin E for non-cirrhotic, non-diabetic individuals with biopsy-confirmed NASH and pioglitazone for managing diabetic patients with biopsy-confirmed NASH.

Vitamin E, recognized for its antioxidant properties, is regarded as an initial pharmacological approach in addressing NASH, particularly when dietary and lifestyle adjustments prove inadequate. Agents with antifibrotic properties can halt the advancement from liver fibrosis and NAFLD to fibrotic NASH. While the impact of pioglitazone (an anti-diabetic agent) on NASH histology in individuals with T2D has been thoroughly established, certain apprehensions linger, including issues like weight gain, fluid retention, cancer risk, and susceptibility to bone fractures.

Additionally, other focuses for treating NAFLD and NASH include G protein-coupled receptors (GPCRs), estrogen-related receptor alpha (ERRα), bone morphogenetic proteins (BMPs), and KLFs. Bariatric surgery, also known as weight loss surgery, is considered the most efficient method to address obesity and diabetes. This procedure works by decreasing food absorption and adjusting gut hormone secretion and metabolic issues.

To know more about NAFLD treatment guidelines, visit @ Non-Alcoholic Fatty Liver Disease Management 

Non-Alcoholic Fatty Liver Disease Pipeline Therapies and Key Companies

• MN-001: MediciNova
• LY3885125: Eli Lilly and Company
• AZD7503: AstraZeneca
• Lanifibranor: Inventiva Pharma
• OA-235i: Oasis Pharmaceuticals, LLC
• Resmetirom: Madrigal Pharmaceuticals, Inc.
• BMN 255: BioMarin Pharmaceutical
• GSK4532990: GlaxoSmithKline
• Saroglitazar Magnesium 4 mg Tablet: Zydus Therapeutics Inc.
• Efruxifermin: Akero Therapeutics, Inc
• PF-06865571: Pfizer
• BI 3006337: Boehringer Ingelheim
• DD01: Neuraly, Inc.
• Efinopegdutide: Merck Sharp & Dohme LLC
• HU6: Rivus Pharmaceuticals, Inc.
• Rencofilstat: Hepion Pharmaceuticals, Inc.

Learn more about the FDA-approved drugs for NAFLD @ Drugs for Non-Alcoholic Fatty Liver Disease Treatment 

Non-Alcoholic Fatty Liver Disease Market Dynamics

The dynamics of the non-alcoholic fatty liver disease market are expected to change in the coming years. The increasing research activities and numerous ongoing clinical trials for NASH indicate a growing number of drug developments that are poised to strengthen the NAFLD market, presenting lucrative opportunities for NAFLD market growth in the 7MM due to the substantial presence of a large pool of patients suffering from NASH.

Furthermore, as many potential therapies are being investigated for the treatment of NAFLD, and it is safe to predict that the treatment space will significantly impact the NAFLD market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the NAFLD market in the 7MM.

However several factors may impede the growth of the non-alcoholic fatty liver disease market. The diagnosis of NASH involves an invasive procedure, and the launch of generics will pose a threat to new emerging therapies due to their cost-effectiveness. Moreover, NAFLD treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the NAFLD market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the NAFLD market growth.

Scope of the Non-Alcoholic Fatty Liver Disease Market Report

• Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and emerging therapies
• Non-Alcoholic Fatty Liver Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Non-Alcoholic Fatty Liver Disease Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement

Discover more about NAFLD drugs in development @ Non-Alcoholic Fatty Liver Disease Clinical Trials

Table of Contents

Related Reports

Non-Alcoholic Fatty Liver Disease Pipeline

Non-Alcoholic Fatty Liver Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NAFLD companies, including BeiGene, Inventiva Pharma, Cirius Therapeutics, Madrigal Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmaceuticals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Enanta Pharmaceuticals, Cascade Pharmaceuticals, among others.

Non-Alcoholic Fatty Liver Disease Epidemiology Forecast

Non-Alcoholic Fatty Liver Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted NAFLD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Nonalcoholic Steatohepatitis Market

Nonalcoholic Steatohepatitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key nonalcoholic steatohepatitis companies, including Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, among others.

Nonalcoholic Steatohepatitis Pipeline

Nonalcoholic Steatohepatitis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonalcoholic steatohepatitis companies, including Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+91-9650213330
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP